Pathologic complete response (pCR) with weekly nanoparticle albumin bound (nab-P) plus carboplatin (C) followed by doxorubicin plus cyclophosphamide (AC) with concurrent bevacizumab (B) for triple-negative breast cancer (TNBC).
Jessica Nicole Snider
No relevant relationships to disclose
Jasgit C. Sachdev
Research Funding - Celgene; Genentech
Jeffrey Warren Allen
No relevant relationships to disclose
Lee Steven Schwartzberg
Honoraria - Roche
Robyn R. Young
Consultant or Advisory Role - Celgene
Honoraria - Genentech
Ahmed Yasir Javed
No relevant relationships to disclose
Furhan Yunus
No relevant relationships to disclose
Carmel S. Verrier
No relevant relationships to disclose
Mohammad Jahanzeb
No relevant relationships to disclose